Introduction
The transcription factor nuclear factor kappaB (NF-kB) regulates immune and inflammatory responses but also promotes cell survival during cancerous transformation. 1 Through transcription of a large array of genes, NF-kB can support cancerous proliferation, resistance to apoptosis and treatments, sustain angiogenesis as well as metastases production. NF-kB is abnormally active in various hematologic malignancies. In acute myeloid leukemia (AML) leukemic blasts, NF-kB exerts strong survival influences. 2 We have shown that pharmacological inhibition of IkappaB kinase-2 (IKK2), the kinase responsible for phosphorylation and inactivation of NF-kB's inhibitory subunit IkB, led to NF-kB inhibition in AML blasts resulting in induction of cell death and increased apoptotic responses to the chemotherapeutic drugs doxorubicin or AraC. 3 The oncogenic mechanisms that activate NF-kB in cancer cells are largely undefined 4 with no exception in AML cells. One interesting possibility in this leukemia is the Fms-like tyrosine kinase 3 (FLT3). FLT3 is expressed on myeloid and lymphoid progenitors to promote their proliferation, differentiation and survival. 5, 6 FLT3 is overexpressed or mutated in a large number of AML cases. 7 In particular, the ITD mutant that harbors a tandem duplication in the kinase domain is detected in 15-35% of the patients and is associated with a poor clinical outcome. 8, 9 Several inhibitors of FLT3 are under clinical evaluation for the treatment of AML. 10, 11 In this article, we have explored the possible link between FLT3 and NF-kB using the murine pre-B cell line Ba/F3 as well as the MV4-11 human AML line. The interleukin-3 (IL)-3 growth dependency of parental Ba/F cells can be shifted upon transfection of various tyrosine kinases that transduce proliferation signals. Expression of FLT3 in Ba/F3 cells renders them dependent on the FLT3 ligand, FL. Moreover, introduction of FLT3-ITD or FLT3 point mutants that are found in some AML patients rendered the cells autonomous for their growth even in the absence of FL. Using these various cell lines, we could demonstrate that FLT3 activation either by its ligand FL or by oncogenic mutations resulted in activation of NF-kB to support cell survival. Pharmacological inhibition of either FLT3 or NF-kB induced proliferation arrest, caspase activation and cell death. Moreover, we observed that the small molecule inhibitor of IKK2 we used to block NF-kB activation was also able to target directly FLT3, therefore affecting two important deregulated signaling components in AML cells.
Materials and methods

Cells
The Ba/F3 cell line is a murine IL-3-dependent pre-B cell line. Expression of FLT3-wild type (WT) or mutants (ITD, D835 V, D835Y) abrogates IL-3 dependence. These variants were established in Dr P Dubreuil's laboratory using plasmids encoding the different mutants of FLT3, kindly provided by Pr T Naoe (Nagoya, Japan). The MV4-11 human cell line obtained from DSMZ (Braunsweig, Germany) was established from a 10-year-old boy with AML FAB M5. MV4-11 cells carries the FLT3 ITD mutation. Cell lines were maintained in Rosewell Park Memorial Institute 1640, supplemented with 10% fetal calf serum, 200 mM L-glutamine, penicillin (200 U/ml) and streptomycin (200 mg/ml). Ba/F3/FLT3-WT were maintained in the same medium supplemented with either IL-3 (10 ng/ml) or FL (10 ng/ml).
Drugs and reagents
AS602868 is an anilinopyrimidine derivative and adenosine triphosphate (ATP) competitor, which inhibits IKK2 (patent application PCTWO 02/46171 
Western blotting
After stimulation, cells were solubilized in lysis buffer (50 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.4, 150 mM NaCl, 20 mM ethylenediaminetetraacetic acid (EDTA), 100 mM sodium fluoride, 10 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl fluoride, 0.5% NP-40) for 30 min at 41C. Lysates were centrifuged at 15 000 g for 10 min at 41C and supernatants were either adjusted with concentrated sodium dodecyl sulfate (SDS) sample buffer or incubated with antibodies for immunoprecipitation experiments as described previously. 12 Proteins were separated by SDS/polyacrylamide gel electrophoresis (PAGE) and transferred to Immobilon membranes (Millipore, Bedford, MA, USA) in a Tris (20 mM), glycine (150 mM) and ethanol (20%) buffer at 500 mA for 4 h at 41C. Antibodies were incubated in saturation buffer (50 mM Tris, pH 7.5, 50 mM NaCl, 0.15% Tween, and 5% bovine serum albumin) and revealed with a secondary-peroxidase-conjugated antibody followed by ECL detection (GE Healthcare, Orsay, France).
Measurement of apoptosis by annexin-V staining
After stimulation, cells (0.5 Â 10 6 ) were harvested by centrifugation and resuspended in 100 ml of commercial binding buffer containing annexin-V-FITC and propidium iodide (PI) for 15 min in the dark. Apoptosis was analyzed on a FACScan (Becton Dickinson) and quantified as percentage of annexin-V and PI-positive cells because in culture well annexin-V-positive cells acquired positivity for PI.
Mitochondrial membrane depolarization
Cells (0.5 Â 10 6 ) were stimulated, harvested, washed with phosphate-buffered saline (PBS) and incubated with 50 nM DiOC6 3 and PI (15 min, 371C). Cells were centrifugated and resuspended in PBS containing 2.5 mM CaCl 2 . DiOC6 3 and PI fluorescence were measured by fluorescence activated cell sorter (FACS).
Measurement of caspase activity by flow cytometry
Cells were permeabilized (41C, 20 min) before staining with anti-active-caspase-3 antibody and cytometry analysis.
Electrophoretic mobility shift assays (EMSA)
Cellular extracts and mobility shift assays were performed as described previously. 12 Briefly, total cell extracts were incubated with a radioactive double-stranded oligonucleotide encompassing the kB site of the Igk promoter. Complexes were separated by nondenaturing electrophoresis followed by autoradiography.
Luciferase assays
Cells were transiently transfected using TransFast (Promega, Madison, WI, USA) according to the manufacturer's instructions with 10 mg of a luciferase reporter gene controlled by a minimal thymidine kinase promoter and six reiterated kB sites (kB Â 6 thymidine kinase luc). At 24 h after transfection, cells were stimulated for 18 h and lysed with reporter lysis buffer (Promega). Soluble extracts were assayed for luciferase activity using the Luciferase Assay Reagent (Promega) on a Centro LB960 luminometer (Berthold, Thoiry, France).
In vitro FLT3 kinase assay
In a final volume of 25 ml, FLT3 (h) (5-10 mU) was incubated with 8 mM MOPS pH 7.0. 0.2 mM EDTA, 50 mM EAIYAAP-FAKKK, 10 mM Mg acetate and g-33P-ATP, (specific activity approximately 500 cpm/pmol, concentration as required). The reaction was initiated by addition of the MgATP mix. After incubation for 40 min at RT, the reaction was stopped by addition of 5 ml of a 3% phosphoric acid solution. 10 ml of the reaction were then spotted onto a P30 filtermat and washed three times for 5 min in 75 mM phosphoric acid and once in methanol prior drying and scintillation counting.
Results
FLT3 engagement activates NF-kB
To determine if FLT3 could stimulate NF-kB, we analyzed NF-kB activation in a gel shift assay on various Ba/F3 variants. In cells expressing the WT form of FLT3, stimulation with FL-induced NF-kB activation ( Figure 1a ) that was detected at 1 h (lane 2) and lasted for 6 h (lane 5). FL-induced NF-kB activation could be suppressed by preincubation with the FLT3 inhibitor AG1296 (lanes 4, 7) or with the IKK2 inhibitor AS602868 (lanes 3, 6). The NF-kB signal was displaced to a slower migration species with an anti-p65 antibody (lane 10), whereas anti-p50 antibodies decreased intensity of the band (lane 13). Antibodies against the other NF-kB family members had no effect (lanes 11, 12) , suggesting that p50-p65 dimers are preferentially activated in Ba/F3 cells. Specificity of the binding was demonstrated after disappearance of the signal in the presence of a 100 or 50 times excess of cold probe (lanes 14 and 15, respectively). 
AS602868 targets FLT3
We analyzed FLT3 activation through measurement of its tyrosine phosphorylation status. After cell stimulation, FLT3 was first immunoprecipitated with specific antibodies, followed by a Western blot analysis with anti-phosphoFLT3 (phosphotyrosine 591) antibodies. The amount of FLT3 was visualized through direct blotting with FLT3 antibodies. Ba/F3/FLT3-WT cells displayed a small constitutive tyrosine phosphorylation of FLT3 owing to its maintenance in culture in the presence of FL and In the absence of any stimulus, the ITD form of FLT3 had a strong constitutive tyrosine phosphorylation (lane 5) that was altered by AG1296 (lane 7) and to a lower extent by AS602868 (lane 6). Constitutive phosphorylation of the D835V mutant (lane 8) was similarly inhibited by AG1296 (lane 10) and AS602868 (lane 9). Phosphorylation of the D835Y mutant of FLT3 (lane 11) was resistant to AG1296 (lane 13), which is known to be less effective on this FLT3 mutation (lane 13) whereas AS602868 had a slight inhibitory effect (lane 12).
Total levels of FLT3 proteins were not affected by stimulation as shown in the lower panel, demonstrating that the two drugs affect tyrosine phosphorylation of FLT3 (lower panels).
An in vitro kinase assay confirmed that AS602868 inhibits activation of recombinant FLT3-WT and -D835Y species with respective half-maximal inhibitory concentration (IC 50 ) of 678 and 1076 nM (Figure 2b ). The effect of AS602868 was then studied on endogenous FLT3-ITD expressed by MV4-11 cells. This mutant is also constitutively phosphorylated on tyrosine residues (Figure 2c , lane 1). Incubation with 10 mM AS602868 (lane 2) or AG1296 (lane 3) resulted in a complete disappearance of phosphoFLT3 without significant differences in expression levels (lower panel).
A FACS analysis (Figure 2d ) demonstrated that AS602868 (1 h) did not significantly affect expression of FLT3 at the surface in Ba/F3/FLT3-ITD, -D835 V, -D835Y and MV4-11 cells. In addition, the effect of AS602868 was intrinsic to this molecule as BMS-345541, another IKK2 inhibitor with a different chemical structure (quinoxaline) had no effect on tyrosine phosphorylation of FLT3 (Figure 2e 
FLT3 and NF-kB activation support Ba/F3 and MV4-11 proliferation
The different cell lines expressing either WT or FLT3 mutants were incubated for 48 h with various doses of AG1296 or Targeting NF-jB and FLT3 in AML E Griessinger et al AS602868 before monitoring cell proliferation by an XTT assay. Figure 3a shows that AS602868 dose-dependently inhibited proliferation of FL-stimulated Ba/F3/FLT3-WT, of Ba/F3 expressing FLT3-ITD, FLT3-D835 V or FLT3-D835Y mutants (Table 1 for IC 50 values). Inhibition of FLT3 with AG1296 dosedependently decreased cell proliferation except for Ba/F3/ FLT3-D835Y. Viability of MV4-11 cells was also dose-dependently decreased by AS602868 or AG1296 (3B). These data show that FLT3 and downstream NF-kB are important for cell viability in these model lines.
Induction of annexin-V staining
During early phases of apoptosis phosphatidylserine molecules migrate from the inner to the outer leaflet of the plasma membrane and can be visualized using fluorescent annexin-V in a FACS analysis. AS602868 dose dependently increased annexin-V staining in the four Ba/F3 variants and when used at 10 mM was as efficient as staurosporine, a known positive effector of apoptosis (Figure 4a ). AS602868 but not AG1296-induced annexin-V staining in Ba/F3/FLT3-D835Y cells (Figure 4b ). In MV4-11 cells, both AS602868 and AG1296 stimulated annexin-V staining in MV4-11 cells although with a lower efficiency (32 and 24%, respectively).
Measurement of mitochondrial depolarization
Caspase activation is preceded by changes in mitochondrial transmembrane potential that can be visualized by flow cytometry using the fluorescent dye DiOC6. As shown in Figure 4d , AS602868 induced a dose-dependent decrease in the mitochondrial potential in the four Ba/F3 cell lines. AG1296 had a similar effect except on the D835Y variant. Staurosporine induced a slightly stronger depolarization in the four lines.
AS602868 decreased Bcl-xL levels
NF-kB interferes with the mitochondrial cell death pathway, particularly by inducing genes coding for the antiapoptotic Bcl-2 family member Bcl-xL. We observed by a Western blotting experiment that a 48 h incubation with 10 mM AS602868 led to a decrease in Bcl-xL protein levels ( Figure 4e, Targeting FLT3 or NF-kB induces caspase-3 activation Caspase-3 activation was investigated by flow cytometry using an antibody against the active form of the protease (Figure 5a ). Staurosporine-induced caspase-3 activation in 72, 49 and 54% of Ba/F3 cells expressing FLT3-WT, -ITD and -D835Y, respectively. AS602868 at 10 mM was less efficient than staurosporine with 56, 25 and 42% of caspase-3 activation in the same lines. The effect of AS602868 appeared dose-dependent and was strongly blocked by preincubation with the pan-caspase inhibitor z-VAD. Incubation of MV4-11 cells with AS602868 also led to caspase-3 activation (29%), whereas AG1296 was less efficient (18%).
Targeting FLT3 or NF-kB induced PARP cleavage
Cleavage of the PARP polymerase from 116 to 89 kDa by caspase-3 is an apoptotic marker. After 24 h with staurosporine, cleavage of PARP was evident in the four Ba/F3/FLT3 lines Cells were cultured for 48 h in the presence of increasing concentration of effectors. Cell viability was assessed using an XTT assay.
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Discussion
Current chemotherapeutic drugs used to treat cancer have antiproliferative actions that make them aggressive not only for cancer cells but also for normal dividing cells, generating strong toxic side effects. Moreover, these treatments have reached a maximum in terms of therapeutic efficiency and much is still required to cure cancer patients. It is therefore crucial to identify, at the level of the different cancerous pathologies and ultimately at the level of individual patients, all the deregulated steps of the tumorigenic process. Future antineoplastic therapies will be designed to target these molecular defects that characterize cancer cells and sustain their cancerous phenotype.
Some drugs of this kind already exist such as Imatinib mesylate that was designed to target the bcr-abl oncogenic tyrosine kinase at the origin of chronic myelogenous leukemia. 13 Moreover, as cancerous cells can develop resistance mechanisms to escape treatments, in particular to targeted therapies, it will be necessary to combine several drugs to affect the deregulated oncogenic pathways. 14 It has been reported that leukemic blasts from AML patients display an abnormal activation of the NF-kB pathway. 2 Inhibition of NF-kB could thus represent an attractive therapy Targeting NF-jB and FLT3 in AML E Griessinger et al for cancer. 15 Although it is easy and highly specific to block NFkB activation after transfection of a super-repressor form of the inhibitory subunit IkB-a 16 this approach is harder in primary cells or in patients. Nevertheless, a large number of compounds that can interfere with the NF-kB pathway have been reported although the specificity of many of them is questionable for a use in clinics. 17 We have used AS602868, a small molecule inhibitor that targets the active form of IKK2 to block NF-kB activation. 18 In a previous study, we described that in vitro this molecule could induce apoptosis of AML primary blasts and synergized with chemotherapeutic drugs. 3 In this article we show in the Ba/F3 cell model that engagement of the hematopoietic growth factor receptor FLT3 by its physiological ligand FL induces NF-kB. Such a link what previously reported in Ba/F3 cells overexpressing FLT3. 19 In addition, we show that constitutive activation of FLT3 by oncogenic mutations such as ITD, D835 V or D835Y also resulted in NF-kB activation. These mutations have been isolated from AML patients and among them expression of FLT3-ITD characterize patients with a poor pronostic. 9 These results were confirmed using the ITD-positive human AML cell line MV4-11. Tyrosine kinases not only transmit mitogenic signals via engagement of the Ras/mitogen-activated protein kinase pathway but also exert survival influences through PI3K/Akt or NF-kB activation. 20 Therefore, interrupting NF-kB downstream of FLT3 could be a means to sensitize cells to apoptotic cell death. Birkenkamp et al. 21 showed that inhibition of FLT3 by AG1296 in primary AML blasts did not affect constitutive NF-kB activation, suggesting that NF-kB could be turned on by FLT3-independent pathways such as the Ras pathway that is frequently mutated or in an active form in AML cases. As mentioned by the authors, it is likely that several signaling routes are activated in AML with overlapping activities towards NF-kB or other molecular events associated with leukemogenesis.
In either solid tumors or hematopoietic malignancies, NF-kB exerts strong antiapoptitic actions by interfering with caspase activation at various levels. 22 Here we show that blocking NF-kB with a pharmacological inhibitor of the IKK2 kinase decreased viability in cells that are dependent on normal or oncogenic FLT3 signaling. Interestingly, oncogenic mutants of FLT3 display a lower IC 50 towards AS602868 than cells expressing the WT form of the receptor. This could be related to the concept of oncogenic addiction and/or to differences in signaling by the different mutants. 23 This response was due, at least in part, to apoptosis induction after disruption of the mitochondrial potential and caspase activation. We observed that AS602868 decreased expression of Bcl-xL an antiapoptotic member of the Bcl-2 mitochondrial protein family, which is important for controlling the mitochondrial cell death pathway. 24 During the course of this study, we unexpectedly observed that AS602868 not only affected IKK2 activation but was also able to directly interfere with FLT3 activation. AS602868 inhibited both FLT3-WT as well as -ITD, -D835 V and -D835Y mutants. In vitro, AS602868 showed an IC 50 of 618 nM towards FLT3 compared to an IC 50 of 70 nM for IKK2 and of more than 3000 for IKK1. As AS602868 inhibits both IKK2 and FLT3 it is difficult to evaluate the relative contribution of inhibition of these two kinases in the apoptotic response. In addition, inhibition of both FLT3 and NF-kB is also expected to directly affect cell proliferation.
Additional experiments will be required, for instance, by comparing the effect of AS602868 on AML patients expressing various levels of FLT3 or mutant forms of FLT3. As FLT3 and NF-kB are important players in proliferation, survival and differentiation of normal hematopoietic or leukemic cells, this dual inhibitory effect of AS602868 on these pathways makes it an attractive molecule to affect AML cells at different levels of their oncogenic process. AS602868 is now entering a clinical trial and results will hopefully confirm these in vitro data and tell if targeting NF-kB is an interesting strategy in leukemia treatment.
